{"entity":{"id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","aka":[],"tldr":"A phase 1/2 trial of TUB-040 + Carbo + BEV in ovarian cancer, run by Tubulis GmbH, now recruiting.","summary":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer is a phase 1/2 interventional study registered as NCT07736937 by Tubulis GmbH, with 72 participants planned, started 2026-03-30 and due to reach its primary completion in 2028-03. Interventions recorded: TUB-040 + Carbo + BEV.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07736937","url":"https://clinicaltrials.gov/study/NCT07736937"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["tubulis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07736937","phase":"1/2","setting":"A Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of TUB-040, in Combination With Standard Ovarian Cancer Drugs in Patients With High-grade Epithelial Serous or Endometrioid Epithelial Ovarian Cancer OC)","sponsor":"Tubulis GmbH","enrolled":72,"outcomes":[]},"route":"/trials/nct07736937/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/"}]}}